• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Forbion European Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    9/13/23 5:05:03 PM ET
    $FRBN
    Blank Checks
    Finance
    Get the next $FRBN alert in real time by email
    8-K
    00-0000000 GRAND CAYMAN false 0001874495 0001874495 2023-09-13 2023-09-13 0001874495 frbn:Class160AOrdinarySharesParValue0.0001PerShareMember 2023-09-13 2023-09-13 0001874495 frbn:RedeemableWarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf11.50Member 2023-09-13 2023-09-13 0001874495 frbn:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneThirdOfOneRedeemableWarrantMember 2023-09-13 2023-09-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    September 13, 2023 (September 13, 2023)

     

     

    FORBION EUROPEAN ACQUISITION CORP.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Cayman Islands   001-41148   N/A

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4001 Kennett Pike, Suite 302

    Wilmington, Delaware

      19807
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: +1 732 838-4533

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A ordinary shares, par value $0.0001 per share   FRBN   The Nasdaq Stock Market LLC
    Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   FRBNW   The Nasdaq Stock Market LLC
    Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant   FRBNU   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

    Additional Working Capital Loan

    On September 13, 2023, Forbion European Acquisition Corp. (the “Company”) issued an additional unsecured promissory note (the “Working Capital Note”) in the total principal amount of $450,000 to Forbion Growth Sponsor FEAC I B.V. (the “Sponsor”). The proceeds of the Working Capital Note will be used by the Company for general working capital purposes. The Sponsor funded the principal amount of $450,000 on September 13, 2023.

    The Working Capital Note bears no interest and shall be due and payable on the earlier of (i) the date of consummation of the Company’s initial merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a “Business Combination”) and (ii) December 14, 2023 (the “Maturity Date”). In the event that the Company does not consummate a Business Combination, the Working Capital Note will be repaid only from amounts remaining outside of the Company’s trust account established in connection with the Company’s initial public offering of its securities (the “IPO” and such trust account the “Trust Account”), if any.

    A failure to pay the principal outstanding amount of the Working Capital Note within five business days following the date when due or the commencement of a voluntary or involuntary bankruptcy action of the Company shall be deemed an event of default, in which case the Sponsor may declare the Working Capital Note due and payable immediately.

    The issuance of the Working Capital Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

    A copy of the Working Capital Note is attached as Exhibit 10.1 to this Current Report on Form 8-K (the “Current Report”) and is incorporated herein by reference. The disclosures set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Working Capital Note.

    Second Business Combination Deadline Extension and Extension Loan Note

    On September 13, 2023, the Company further extended the time available to consummate its Business Combination from September 14, 2023 to December 14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account (the “Extension Funding”), in accordance with the Company’s Amended and Restated Memorandum and Articles of Association and the Investment Management Trust Agreement by and between the Company and Continental Stock Transfer & Trust Company, dated as of December 9, 2021.

    In connection with the Extension Funding, on September 13, 2023, the Company issued an unsecured promissory note (the “Extension Note”) in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of $1,265,000 by depositing such amount into the Trust Account on September 13, 2023.


    The Extension Note bears no interest and shall be due and payable on the earlier of (i) the date of consummation of the Business Combination and (ii) the Maturity Date. In the event that the Company does not consummate a Business Combination, the Extension Note will be repaid only from amounts remaining outside of the Trust Account, if any.

    A failure to pay the principal outstanding amount of the Extension Note within five business days following the date when due or the commencement of a voluntary or involuntary bankruptcy action of the Company shall be deemed an event of default, in which case the Sponsor may declare the Extension Note due and payable immediately. The issuance of the Extension Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

    A copy of the Extension Note is attached as Exhibit 10.2 to this Current Report and is incorporated herein by reference. The disclosures set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Extension Note.

    Forward-Looking Statements

    The information in this Current Report includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding FEAC’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Current Report may include, for example, statements regarding FEAC’s ability to consummate the Business Combination.

    All forward-looking statements are based on estimates and assumptions that, while considered reasonable by FEAC and its management are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond FEAC’s control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and should not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of FEAC. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. These risks and uncertainties include the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; the outcome of any legal proceedings that may be instituted against FEAC following this Current Report; the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of FEAC, or to satisfy other conditions to closing; changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; the ability of the combined company to meet stock exchange listing standards following the consummation of the Business Combination, the combined company’s ability to raise additional capital to fund its produce development activity, and its ability to maintain key relationships and to attract and retain talented personnel; costs related to the Business Combination; changes in applicable laws or regulations; the possibility that the combined company may be adversely affected by changes in domestic and foreign business, market, financial, political, legal conditions and laws and regulations; the inability of the parties to successfully or timely consummate the Business Combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Business Combination; or other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary” in FEAC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, or other documents filed or to be filed from time to time by FEAC with the SEC.


    Any forward-looking statement speaks only as of the date on which it was made. FEAC anticipates that subsequent events and developments will cause FEAC’s assessments to change. While FEAC may elect to update these forward-looking statements at some point in the future, FEAC specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this Current Report should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

    FEAC disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this Current Report and such liability is expressly disclaimed.

    Participants in the Solicitation

    FEAC and its directors, managers, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from FEAC’s shareholders with respect to the Business Combination under the rules of the SEC. FEAC’s investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of FEAC’s directors and officers, without charge, in FEAC’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement/prospectus and the amendments thereto, the definitive proxy statement/prospectus, and other documents filed with the SEC.

    No Offer or Solicitation

    This Current Report is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    10.1    Working Capital Promissory Note dated September 13, 2023, issued by Forbion European Acquisition Corp. to Forbion Growth Sponsor FEAC I B.V.
    10.2    Extension Promissory Note dated September 13, 2023, issued by Forbion European Acquisition Corp. to Forbion Growth Sponsor FEAC I B.V.
    104    Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: September 13, 2023

     

    FORBION EUROPEAN ACQUISITION CORP.
    By:  

    /s/ Jasper Bos

      Jasper Bos
      Chief Executive Officer
    Get the next $FRBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRBN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRBN
    SEC Filings

    View All

    SEC Form 15-12G filed by Forbion European Acquisition Corp.

    15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/13/23 6:45:16 AM ET
    $FRBN
    Blank Checks
    Finance

    Forbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/1/23 5:53:05 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Forbion European Acquisition Corp.

    25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)

    10/31/23 5:07:48 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    enGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies

    Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen

    5/17/23 7:00:28 AM ET
    $FRBN
    Blank Checks
    Finance

    VectivBio Announces Results of Extraordinary General Meeting

    BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio

    12/9/22 4:01:00 PM ET
    $FRBN
    $VECT
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Forbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 7:05:31 PM ET
    $FRBN
    Blank Checks
    Finance

    Forbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:59:26 PM ET
    $FRBN
    Blank Checks
    Finance

    New insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)

    3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:12:51 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 4:55:28 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G filed by Forbion European Acquisition Corp.

    SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 6:00:38 AM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/8/24 12:51:47 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance